Aranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:
- Myocardial infarction, or heart attack, as well as congestive heart failure
Hypertension (high blood pressure), with increased risk of stroke
- Venous thromboembolism
- Thrombosis of vascular access
- Tumor progression or recurrence
If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Happy 4th of July
Our country is not the only thing to which we owe our allegiance. It is also owed to justice and to…Read More 02 Jul 2020, Thursday
Supreme Court Issues Landmark LGBT Employment Law Ruling
Decision Applies Civil Rights Act to Employment Issues in All 50 States The United States Supreme Co…Read More 25 Jun 2020, Thursday
President Seeks to Limit Liability of Meat Companies for COVID-19
Industry Continues to Be Hotspot for COVID Infection State health officials in Idaho announced on Tu…Read More 09 Jun 2020, Tuesday